Video: make pooling of patents and knowledge work to end the pandemic

To end the corona pandemic as quickly as possible, we need to maximize the production of Covid-19 vaccines. The few pharmaceutical companies that currently produce safe and effective vaccines, should share their patent rights and knowledge, so other manufacturers can produce vaccines as well. Governments and pharmaceutical companies around the world: make pooling work!

Q&A on pooling patents and knowledge

Read our Q&A on pooling patents and knowledge for Covid-19 vaccines

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent News items

Milestone: research institute shares patents and know-how globally through C-TAP

24-11-2021

Wemos is delighted that the Spanish National Research Council (CSIC) shares its intellectual property and know-how for the production of its Covid-19 diagnostic tool with the Covid-19 Technology Access Pool (C-TAP) of the World Health Organization (WHO). As such, CSIC permits all qualified manufacturers worldwide to make the product and distribute it to any country in the world, royalty-free for low- and middle-income countries. This is the first global, non-exclusive license for a Covid-19 innovation and thus a milestone for equal access to medical products.

Continue reading

Pfizer’s knowledge sharing on antiviral is positive step, but more is needed

16-11-2021

The US pharmaceutical company Pfizer will share its intellectual property and know-how for the production of its Covid-19 pill in the Medicines Patent Pool (MPP). The company is following the example of Merck & Co (MSD) that recently announced the same. This is an important step in the right direction to enhance global access to medical products against Covid-19. Wemos is calling on Pfizer and other vaccine makers to do the same for their vaccines.

Continue reading